Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Admilparant by Bristol-Myers Squibb for Pulmonary Fibrosis: Likelihood of Approval
Admilparant is under clinical development by Bristol-Myers Squibb and currently in Phase III for Pulmonary Fibrosis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Admilparant?
Admilparant is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Pulmonary Fibrosis. According to...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Admilparant?
Admilparant is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Idiopathic Pulmonary Fibrosis. According...